Kailera Therapeutics

KLRA · NASDAQ

$12.89+$1.46 (+12.77%)TodayMarket closed ·
Prev close $11.43

Latest news

  • Press releaseGlobe Newswire

    Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

  • Press releaseGlobe Newswire

    Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection

  • Press releaseGlobe Newswire

    Kailera Therapeutics to Participate in September Investor Conferences

  • NewsAvi Kapoor

    Jim Cramer Recommends Buying This Energy Stock, Calling It ‘Very Inexpensive’

  • Press releaseGlobe Newswire

    Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

  • Press releaseGlobe Newswire

    Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer

  • NewsVandana Singh

    Why Is Kailera Therapeutics Stock Falling Tuesday?

  • Press releaseGlobe Newswire

    Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535

  • Press releaseGlobe Newswire

    Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

  • Press releaseGlobe Newswire

    Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

  • Press releaseGlobe Newswire

    Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

  • Press releaseGlobe Newswire

    Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

  • NewsBamboo Works

    Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy

  • Press releasePRNewswire

    Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

  • NewsVandana Singh

    Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.